Thakur Nitin, Kumar Tarun, Singh Charan, Kumar Raj, Kumar Arun
Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya 824209, India.
Department of Pharmaceutical Sciences, School of Sciences, Hemvati Nandan Bahuguna, Garhwal University (A Central University), Srinagar, Uttarakhand 246174, India.
Int J Pharm. 2025 Aug 20;681:125875. doi: 10.1016/j.ijpharm.2025.125875. Epub 2025 Jun 20.
Neurodegenerative disorders (ND) are accompanied by neuronal death because of progressive destruction in neuronal structure and function. Due to various neurological conditions, there is a significant number of deaths every year around the world. The healthcare burden is also increasing each year. Development and progress in nanotechnology enable the creation of nanocarriers that transport drugs to the site of disease, thereby enhancing the therapeutic performance of the drug. However, the transport of nanocarrier-based therapeutics to the brain is restricted by barriers such as the Blood-Brain Barrier (BBB) and Blood-Cerebrospinal Fluid Barrier (BCFB), which are further impeded by P-glycoproteins. Hence, current research and development focus on overcoming these obstacles. A biomimetic drug delivery system is one of the best ways to overcome these challenges. One of the promising biomimetic drug delivery systems is cell membrane-coated nanoparticles. In this review, we have comprehensively reviewed the recent progress and development in various cell membrane coated nanoparticle-based drug delivery systems for the effective management of a range of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Glioblastoma, Ischemic Stroke, Huntington's Disease, Amyotrophic Lateral Sclerosis, Glioma, Peripheral Nerve Injury, and Motor Neuron Disorder. We also reviewed the challenges associated with cell membrane-coated nanoparticles, such as biosafety hurdles, toxicity, regulatory requirements, and clinical translation. Ultimately, we provided the conclusions and future research directions that must be investigated to overcome the current limitations.
神经退行性疾病（ND）伴随着神经元死亡，这是由于神经元结构和功能的逐渐破坏所致。由于各种神经疾病，全球每年有大量死亡病例。医疗负担也在逐年增加。纳米技术的发展与进步使得能够制造出将药物输送到疾病部位的纳米载体，从而提高药物的治疗效果。然而，基于纳米载体的治疗药物向大脑的输送受到血脑屏障（BBB）和血脑脊液屏障（BCFB）等屏障的限制，而P-糖蛋白又进一步阻碍了药物输送。因此，当前的研发重点是克服这些障碍。仿生药物递送系统是克服这些挑战的最佳方法之一。有前景的仿生药物递送系统之一是细胞膜包被的纳米颗粒。在本综述中，我们全面回顾了各种基于细胞膜包被纳米颗粒的药物递送系统在有效管理一系列神经退行性疾病（如阿尔茨海默病、帕金森病、胶质母细胞瘤、缺血性中风、亨廷顿舞蹈病、肌萎缩侧索硬化症、胶质瘤、周围神经损伤和运动神经元疾病）方面的最新进展。我们还回顾了与细胞膜包被纳米颗粒相关的挑战，如生物安全障碍、毒性、监管要求和临床转化。最后，我们给出了结论以及为克服当前局限性必须开展研究的未来研究方向。
